| Drug Type Small molecule drug | 
| Synonyms Aclatonium napadisilate (JAN), SKF-100916-J, TM-723 + [1] | 
| Target | 
| Action agonists | 
| Mechanism mAChRs agonists(Muscarinic acetylcholine receptor agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date Japan (01 Jan 1981),  | 
| Regulation- | 
| Molecular FormulaC30H46N2O14S2 | 
| InChIKeyHELVYVGHOJPCEV-UHFFFAOYSA-L | 
| CAS Registry55077-30-0 | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Gastrointestinal motility disorder | Japan  | 01 Jan 1981 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Biliary Dyskinesia | Phase 1 | China  | 22 Dec 2017 | |
| Feeding and Eating Disorders | Phase 1 | China  | 22 Dec 2017 | |
| Gastritis | Phase 1 | China  | 22 Dec 2017 | |
| Nausea | Phase 1 | China  | 22 Dec 2017 | |
| Vomiting | Phase 1 | China  | 22 Dec 2017 | 





